Buckwheat breakthrough? diet shows promise for hypertension
NCT ID NCT04403347
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed pilot study tested whether a special diet made from tartary buckwheat could help lower blood pressure in 130 adults with mild hypertension. Participants added the buckwheat formulation to their regular meals and were compared to those receiving standard care. The study also looked at how the diet might change gut bacteria, which could play a role in blood pressure control.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- tartary buckwheat dietary formulation
- What this could lead to
- If it works, this could point toward a natural dietary supplement to help control mild high blood pressure.
- What could go wrong
- This is a small, early pilot study with no blinding or placebo control. Results may not apply to everyone, and the diet may not lower blood pressure significantly.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
130 people
The number who actually took part.
- Started
-
Jul 2021
- Finished
-
Sep 2024
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 60 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Age 18\~60 years. 2. Established Diagnosis of Grade 1 Hypertension (initial diagnosis or free from antihypertensive drugs within a month): 140mmHg≤ Office SBP\<160mmHg for three measurements at different days without any antihypertensive medications, according to the "2010 Chinese Guidelines for Prevention and Treatment of Hypertension". 3. Patients with informed consent after thorough explanation. Exclusion Criteria: 1. Antibiotics or probiotics usage within last 4 weeks 2. Participants of other clinical trials related to hypertension currently or within last 3 months 3. Antihypertensive medications usage currently or within last month 4. Diagnosed secondary hypertension 5. Severe hepatic or renal diseases ((ALT \>3 times the upper limit of normal value, or end stage renal disease on dialysis or eGFR \<30 mL/min/1.73 m2, or serum creatinine \>2.5 mg/dl \[\>221 μmol/L\]) 6. History of large atherosclerotic cerebral infarction or hemorrhagic stroke (not including lacunar infarction and transient ischemic attack \[TIA\]) 7. Hospitalization for myocardial infarction within last 6 months; Coronary revascularization (PCI or CABG) within last 12 months; Planned for PCI or CABG in the next 12 months. 8. Sustained atrial fibrillation or arrhythmias at recruitment disturbing the electronic BP measurement. 9. NYHA class III-IV heart failure; Hospitalization for chronic heart failure exacerbation within last 6 months. 10. Severe valvular diseases; Potential for surgery or percutaneous valve replacement within the study period. 11. Dilated cardiomyopathy; Hypertrophic cardiomyopathy; Rheumatic heart disease; Congenital heart disease. 12. Other severe diseases influencing the entry or survival of participants, such as malignant tumor or acquired immune deficiency syndrome. 13. Cognitive impairment or severe neuropsychiatric comorbidities who are incapable of providing their own informed consent. 14. Participants preparing for or under pregnancy and/or lactation. 15. Other conditions inappropriate for recruitment according to the investigators.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Hypertension are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Pinggu Hospital
Beijing, Beijing Municipality, China
-
Clinical Medical College&Affiliated Hospital of Chengdu University
Chengdu, Sichuan, China
-
First Affiliated Hospital of Chongqing Medical University
Chongqing, China
-
First Affiliated Hospital of Jinan University
Guangzhou, Guangdong, China
-
Fuwai Hospital, Chinese Academy of Medical Sciences
Beijing, China
-
Longgang District People's Hospital of Shenzhen
Shenzhen, Guangdong, China
-
Second Affiliated Hospital of Shantou University Medical College
Shantou, Guangdong, China
-
the People's Hospital of Ji Xian District
Tianjin, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Inflatable leg cuffs tested as a Two-for-One therapy for high blood pressure and erectile dysfunction
- Can nurses and home monitors tame high blood pressure?
- Can pressing six points on the body help older adults sleep?
- Can AI-Tailored heat warnings shield chronic disease patients from dangerous temperatures?
- Could a quieter, automated blood pressure check help more people control hypertension?
- Can a phone call boost confidence in managing high blood pressure?